GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Inventories, Finished Goods

Reunion Neuroscience (TSX:REUN) Inventories, Finished Goods : C$0.00 Mil (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Inventories, Finished Goods?


Reunion Neuroscience Inventories, Finished Goods Historical Data

The historical data trend for Reunion Neuroscience's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Inventories, Finished Goods Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Inventories, Finished Goods
- - - -

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Reunion Neuroscience Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.

Reunion Neuroscience (TSX:REUN) Headlines